Navigation Links
Vermillion Announces Positive Top-Line Results from the OVA500 Multi-Center Study Led by UC Irvine
Date:7/30/2012

work brings the total number of prospectively enrolled patients in OVA1 clinical studies to more than 1,000, with a total of 259 malignancies. Combined, the studies included 84 early-stage ovarian malignancies of which OVA1 correctly identified 78, for a combined risk stratification (stand-alone) sensitivity of approximately 93%. This key statistic confirms the unrivaled sensitivity of OVA1 for early-stage adnexal malignancies in the critical population of pre-menopausal women, which may aid in pre-surgical detection, referral and prevention of second surgeries.

"These new results point to the possibility of a standardized triage protocol using OVA1, with high sensitivity for all ovarian malignancies including the most curable early-stage cases and a broad range of subtypes," noted Dr. Bristow. "We are especially excited that the sensitive detection of ovarian cancer was paired with the classification of most benign masses as low-risk, and greater than 95% confidence that a negative test will result in a benign pathology finding. Thanks to diagnostic advances like OVA1, there is real hope that the majority of women with ovarian cancer will undergo surgery by a qualified gynecologic oncologist, which is one of the most powerful determinants of survival."

Dr. Bristow is an internationally recognized expert in the surgical management of advanced gynecologic cancer including ovarian, fallopian tube, primary peritoneal, and endometrial cancers. He is the author of four books on ovarian cancer and has published extensively in the field of ovarian cancer research. He is also an experienced minimally invasive surgeon with special expertise in robotic hysterectomy and surgical staging for endometrial cancer and cervical cancer, and was recently named as one the Best Doctors in America for gynecologic cancers by Best Doctors, Inc.

For additional information about Vermillion, contact Liolios Group at 949-574-3860 or email

SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vermillion PAD Intended Use Study Presented at Society for Vascular Medicine 23rd Annual Scientific Sessions
2. Vermillion Announces CEO Succession Plan
3. Vermillion Sets First Quarter 2012 Conference Call for Tuesday, May 15, 2012 at 4:30 p.m. ET
4. Insmed Announces Planned Departure Of Chief Financial Officer
5. Absorption Systems announces novel test platform for interactions with the BCRP transporter
6. Novogen Announces Merger Agreement With Kai Medical And Distribution Of Mei Pharma Shares
7. Aethlon Medical Announces the Appointment of Thomas V. Wornham and Philip A. Ward to its Board of Directors
8. IRIDEX Announces Second Quarter 2012 Conference Call and Release Date
9. Gentris Corporation Announces Collaboration to Study Blood Stability
10. RoundTable Healthcare Partners Announces Sale of Aspen Surgical Products Holding, Inc. to Hill-Rom Holdings, Inc.
11. Biomet Announces Pricing of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)...   Royal Philips (NYSE: ... received 510(k) clearance from the U.S. Food and ... for Transcatheter Aortic-Valve Implantation (TAVI) treatments. Through 3D ... pre-procedural, high-precision positioning to treat aortic stenosis ailments.  ... available as part of Philips IntelliSpace Portal ...
(Date:8/21/2014)... JOSE, Calif. , Aug. 21, 2014  SI-BONE, ... medical device company that pioneered the use of the ... (MIS) device indicated for fusion of the sacroiliac (SI) ... ) published an update to its Lumbar Fusion Medical ... SI joint fusion procedure.  The policy states that the ...
(Date:8/21/2014)... 2014   Auxilium Pharmaceuticals, Inc. (NASDAQ: ... today announced positive results from a randomized, double-blind ... CCH) for the treatment of edematous fibrosclerotic panniculopathy ... 2a trial, all three doses of CCH (low ... improvement in the appearance of cellulite as measured ...
Breaking Medicine Technology:Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7
... May 9 Osteoarthritis is a,painful and ... people in the United States. It is ... The novel investigational pain medication,tapentadol, a centrally ... with joint-disease pain, compared to those treated ...
... Biosciences, Inc.,(Nasdaq: RDEA ), a company focused ... for the treatment of HIV, cancer and,inflammatory diseases, ... been appointed Senior Vice President, Finance and Operations ... will resign from our board of,directors shortly thereafter. ...
Cached Medicine Technology:Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 2Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 3Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 4Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 2Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 3Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 4Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 6
(Date:8/21/2014)... STOCKHOLM, SWEDEN (PRWEB) August 21, 2014 ... today that this year's conference will focus on ... be expected for research, innovation and commercialization. , ... successful ventures, SALSS combines the worlds' of business ... to a widely recognized Summit, gathering a diverse ...
(Date:8/21/2014)... News) -- In a new review of seafood safety, ... tuna due to concerns about mercury exposure. "We,re ... to shrimp as the most commonly eaten seafood in ... all tuna," Jean Halloran, director of food policy initiatives ... said in a news release from the group. ...
(Date:8/21/2014)... (HealthDay News) -- Using two types of polio vaccines ... may boost efforts to eradicate polio, a new study ... India found that giving the Salk inactivated poliovirus vaccine ... Sabin live-attenuated oral poliovirus vaccine (OPV) appeared to improve ... The findings, reported in the Aug. 22 issue of ...
(Date:8/21/2014)... 2014 The Onder Law Firm, nationally-renowned ... law, announces the launch of a new Morcellator Cancer ... morcellator surgery lawsuits for cancer claims, including ... warning and the July 2014 morcellator recall. , ... 2014 FDA warning on morcellator surgery and cancer, federal ...
(Date:8/21/2014)... 2014. Researchers have published a study examining racial ... with motor complete spinal cord injury (SCI). The ... discharge and follow-up among patients with motor complete ... August 2 by the Archives of Physical ... small but significant differences in self-care and mobility ...
Breaking Medicine News(10 mins):Health News:The Tenth Swedish-American Life Science Summit, takingplace in Stockholm, Sweden, August 20-22nd, will focus on The Future of Medicine 2Health News:Consumer Reports Advises Pregnant Women to Avoid Tuna 2Health News:Two Polio Vaccines May Give Greater Protection Against Crippling Disease 2Health News:The Onder Law Firm Launches National Morcellator Cancer Lawsuit Center Website for Morcellator Surgery Lawsuits at MorcellatorCancerLawsuitCenter.com 2Health News:The Onder Law Firm Launches National Morcellator Cancer Lawsuit Center Website for Morcellator Surgery Lawsuits at MorcellatorCancerLawsuitCenter.com 3Health News:Researchers examine impact of race and ethnicity in motor complete spinal cord injury 2
... Organizations, Advocates, Government Agencies, and Scientists from Academic Institutions ... ... 13 Leadership and senior staff of,twenty- seven breast ... along with experts from government agencies, scientists,from academic institutions ...
... Society of America (GSA) has chosen W. Andrew Achenbaum ... of the Donald P. Kent Award. This distinguished honor ... exemplifies the highest standards for professional leadership in gerontology ... larger society. , The award presentation will take ...
... has chosen Nancy L. Pedersen of Sweden,s Karolinska Institutet ... Contribution to Gerontology. This prize is given annually to ... a new synthesis and perspective or have yielded original ... the literature. , The award presentation will take place ...
... operated on, or the wrong transplant, study found , , TUESDAY, ... in eye surgery, say U.S. researchers who analyzed 106 cases ... the wrong site or using wrong procedure. , The ... College in New York found: , The most common ...
... Nov. 13 Green Earth Waterless Carwash, the,only Los ... products and auto detailing services, today announced an agreement,with ... month as part of,the hospital,s employee appreciation program. An ... to the hospital. "We originally signed on for ...
... - Seattle & King County and RediClinic, offers Seattle-area residents a, convenient opportunity to get ... themselves and the many lives they touch, - Vaccination ... ... between mid ...
Cached Medicine News:Health News:First-Ever Collaborative Summit on Breast Cancer Research Targets New Partnerships and Collaborative Solutions 2Health News:First-Ever Collaborative Summit on Breast Cancer Research Targets New Partnerships and Collaborative Solutions 3Health News:First-Ever Collaborative Summit on Breast Cancer Research Targets New Partnerships and Collaborative Solutions 4Health News:Eye Surgery Errors Rare But Serious 2Health News:Childrens Hospital Los Angeles Turns Off the Tap With Green Earth Waterless Carwash 2Health News:Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 2Health News:Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 3Health News:Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 4Health News:Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 5Health News:Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 6
The AMY method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of amylase activity in serum, plasma and urine....
The GLU method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of glucose in serum, plasma, urine and cerebrospinal fluid....
Enzymatic Clearance assay for the in vitro quantitative determination of LDL-cholesterol in human serum and plasma....
For the quantitative in vitro determination of Lipase in human serum and plasma....
Medicine Products: